IRON HORSE DIAGNOSTICS, INC.

Medtech · Private

Blood and CSF biomarker assays (pNfH and complement C3) for ALS diagnosis and prognosis

Grants
$142K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
0 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · Commercialization of a Diagnostic test for amyotrophic lateral sclerosis (ALS)$137,106
Federal grantDepartment of Health and Human Services · Phase II · Commercialization of a Diagnostic test for amyotrophic lateral sclerosis (ALS)$5,000
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
769LinkDyn Robotics Inc.——
770Wield LLC——
771MOSAIC LOFT——
772IRON HORSE DIAGNOSTICS, INC.——
773ETECT, INC.——
774VITI, INC.——
775OPTAVE DIAGNOSTICS LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 2
  • Traumatic Brain Injury and Neurodegenerative Biomarkers, Methods, and Systemsapplication
  • Traumatic Brain Injury And Neurodegenerative Biomarkers, Methods, And Systemsapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.